Sustainability of C-Reactive Protein Apheresis in Acute Myocardial Infarction—Results from a Supplementary Data Analysis of the Exploratory C-Reactive Protein in Acute Myocardial Infarction-1 Study

In the multicenter, non-randomized, exploratory C-reactive protein (CRP) Apheresis in Myocardial Infarction (CAMI-1) study, CRP apheresis after ST-Elevation Myocardial Infarction (STEMI) significantly decreased blood CRP concentrations in humans. Cardiac damage was assessed by Cardiac Magnetic Resonance (CMR1) 3–9 d after onset of STEMI symptoms and quantified by myocardial infarct size (IS; %), left ventricular ejection fraction (LVEF; %), circumferential strain (CS) and longitudinal strain (LS). Compared with the control group (n = 34), cardiac damage was significantly lower in the apheresis group (n = 32). These findings suggested improved wound healing due to CRP apheresis already within few days after the STEMI event. In the current supplementary data analysis of CAMI-1, we have tested by a follow-up CMR (CMR2) after an average of 88 (65–177) d whether the effect of CRP apheresis is clinically maintained. After this time period, wound healing in STEMI is considered complete. Whereas patients with low CRP production and a CRP gradient cut off of <0.6 mg/L/h in the hours after STEMI (9 of 32 patients in the CRP apheresis group) did not significantly benefit from CRP apheresis in CMR2, patients with high CRP production and a CRP gradient cut off of >0.6 mg/L/h (23 of 32 patients in the CRP apheresis group) showed significant treatment benefit. In the latter patients, CMR2 revealed a lower IS (−5.4%; p = 0.05), a better LVEF (+6.4%; p = 0.03), and an improved CS (−6.1%; p = 0.005). No significant improvement, however, was observed for LS (−2.9%; p = 0.1). These data suggest a sustained positive effect of CRP apheresis on heart physiology in STEMI patients with high CRP production well beyond the period of its application. The data demonstrate the sustainability of the CRP removal from plasma which is associated with less scar tissue.

[1]  M. Buerke,et al.  CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19 , 2022, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[2]  M. Buerke,et al.  [CRP apheresis in acute myocardial infarction and COVID-19]. , 2022, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[3]  P. Brunner,et al.  Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons , 2022, Journal of clinical medicine.

[4]  A. Hochstadt,et al.  Association between C-Reactive Protein Velocity and Left Ventricular Function in Patients with ST-Elevated Myocardial Infarction , 2022, Journal of clinical medicine.

[5]  D. Sorysz,et al.  Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with myocardial infarction treated with percutaneous coronary intervention. , 2021, Polish archives of internal medicine.

[6]  A. Mayr,et al.  Association of C-Reactive Protein Velocity with Early Left Ventricular Dysfunction in Patients with First ST-Elevation Myocardial Infarction , 2021, Journal of Clinical Medicine.

[7]  P. Nordbeck,et al.  C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study , 2021, Frontiers in Cardiovascular Medicine.

[8]  T. Rakowski,et al.  Circulating biomarkers as predictors of left ventricular remodeling after myocardial infarction , 2021, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

[9]  P. Brunner,et al.  C-Reactive Protein Triggers Cell Death in Ischemic Cells , 2021, Frontiers in Immunology.

[10]  A. Mayr,et al.  High sensitivity C-reactive protein is associated with worse infarct healing after revascularized ST-elevation myocardial infarction. , 2020, International journal of cardiology.

[11]  A. Mebazaa,et al.  A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2) , 2019, BMJ Open.

[12]  C. Garlichs,et al.  “First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction , 2018, Case reports in cardiology.

[13]  S. Achenbach,et al.  C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty , 2017, Archives of medical science : AMS.

[14]  S. Prabhu,et al.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.

[15]  E. Ohman,et al.  Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.

[16]  A. Arai Healing After Myocardial Infarction: A Loosely Defined Process. , 2015, JACC. Cardiovascular imaging.

[17]  Daniel C. Lee,et al.  Infarct healing is a dynamic process following acute myocardial infarction , 2012, Journal of Cardiovascular Magnetic Resonance.